Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4468748 | PMC |
| http://dx.doi.org/10.4103/1673-5374.156944 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Delayed Stevens-Johnson syndrome induced by combined administration of carbamazepine and botulinum toxin: A case report.
Medicine (Baltimore)
January 2025
Department of Rehabilitation Medicine, Hebei General Hospital, Shijiazhuang, Hebei, China.
Rationale: Steven-Johnson syndrome (SJS) is characterized by severe illness, rapid progression, and high mortality rates, with the vast majority of cases induced by medications. Botulinum toxin, a neurotoxin produced by Clostridium botulinum, has not been reported in the literature as a causative agent of SJS.
Patient Concerns: A 56-year-old male patient, who underwent surgery for cerebral hemorrhage, developed widespread patchy annular papules following the injection of botulinum toxin into the masseter muscle.
Schwann Cells in Neuromuscular Disorders: A Spotlight on Amyotrophic Lateral Sclerosis.
Cells
January 2025
Department of Physical Medicine and Rehabilitation, University of Missouri School of Medicine, Columbia, MO 65211, USA.
Amyotrophic Lateral Sclerosis (ALS) is a complex neurodegenerative disease primarily affecting motor neurons, leading to progressive muscle atrophy and paralysis. This review explores the role of Schwann cells in ALS pathogenesis, highlighting their influence on disease progression through mechanisms involving demyelination, neuroinflammation, and impaired synaptic function. While Schwann cells have been traditionally viewed as peripheral supportive cells, especially in motor neuron disease, recent evidence indicates that they play a significant role in ALS by impacting motor neuron survival and plasticity, influencing inflammatory responses, and altering myelination processes.
View Article and Find Full Text PDFBrain health: Pathway to primary prevention of neurodegenerative disorders of environmental origin.
J Neurol Sci
January 2025
Graduate School of International Development, Nagoya University, Nagoya, Japan.
While rising global rates of neurodegenerative disease encourage early diagnosis and therapeutic intervention to block clinical expression (secondary prevention), a more powerful approach is to identify and remove environmental factors that trigger long-latencybrain disease (primary prevention) by acting on a susceptible genotype or acting alone. The latter is illustrated by the post-World War II decline and disappearance of Amyotrophic Lateral Sclerosis and Parkinsonism-Dementia Complex (ALS/PDC), a prototypical often-familial neurodegenerative disease formerly present in very high incidence on the island of Guam. Lessons learned from 75 years of investigation on the etiology of ALS/PDC include: the importance of focusing field research on the disease epicenter and patients with early-onset disease; soliciting exposure history from patients, family, and community to guide multidisciplinary biomedical investigation; recognition that disease phenotype may vary with exposure history, and that familial brain disease may have a primarily environmental origin.
View Article and Find Full Text PDFRheumatoid Arthritis and COVID-19 at the Intersection of Immunology and Infectious Diseases: A Related PRISMA Systematic Literature Review.
Int J Mol Sci
October 2024
Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 020022 Bucharest, Romania.
Article Synopsis
- Rheumatoid arthritis (RA) patients experience unique challenges when infected with SARS-CoV-2 due to their immunocompromised status and treatments, which complicates their health outcomes compared to the general population.
- The systematic review, adhering to PRISMA guidelines, analyzed literature from 2021-2023 and highlighted issues such as delays in treatment due to COVID-19 fears and increased risk of severe outcomes tied to cardiovascular and metabolic conditions.
- Additionally, the review found that while COVID-19 vaccines are generally safe for RA patients, certain treatments like Methotrexate and Rituximab may weaken their vaccine response, emphasizing the need for tailored medical management during the pandemic.
AAV gene therapy for Duchenne Muscular Dystrophy: lessons learned from a phase 3 trial.
Gene Ther
November 2024
The Dubowitz Neuromuscular Centre, Developmental Neuroscience Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, NIHR Great Ormond Street Hospital Biomedical Research Centre & Great Ormond Street Hospital NHS Foundation Trust, 30 Guilford Street, London, UK.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!